RecruitingNot ApplicableNCT07248176

Universal CAR-T Cell Therapy for MM

A Clinical Study on the Safety and Efficacy of Allogeneic CAR T Cells Targeting BCMA in the Treatment of Adult r/r Multiple Myeloma

Sponsor

Bioray Laboratories

Enrollment

6 participants

Start Date

Apr 10, 2025

Study Type

INTERVENTIONAL

Conditions

This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.

Min Age: 18 Years

Expected survival of at least 3 months;
Subjects should have measurable disease that meets the IMWG 2016 criteria;
Previously received at least two lines of prior anti-myeloma therapy ；
Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；
BCMA positive；
ECOG score 0-1；
No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function.

Pregnant or breastfeeding women;
History of other malignant tumors;
Active autoimmune diseases requiring immunotherapy;
Previously received allogeneic stem cell transplantation;
Previous use of CAR-T cells or other genetically modified T cell therapies;
Previously received targeted BCMA therapy;
Severe cardiovascular disease;
Active infection;
Positive virology test;
Clinically significant central nervous system (CNS) diseases or pathological changes.

DRUGTargeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection

The study drug is administered intravenously at a fixed dose within 1-2 days after lymphocyte depletion, and its efficacy and safety are observed.

Shanghi Tongji Hospital (Tongji Hospital of Tongji University)

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT07248176